A phase II study of gemcitabine, ifosfamide, and oxaliplatin (GIFOX) as upfront treatment for high-risk, non-anaplastic large cell, peripheral T-cell lymphomas.
Gaetano Corazzelli
No relevant relationships to disclose
Gianpaolo Marcacci
No relevant relationships to disclose
Ferdinando Frigeri
No relevant relationships to disclose
Gaetana Capobianco
No relevant relationships to disclose
Francesco Volzone
No relevant relationships to disclose
Cristina Becchimanzi
No relevant relationships to disclose
Daniela Donnarumma
No relevant relationships to disclose
Rosa Azzaro
No relevant relationships to disclose
Rosaria De Filippi
No relevant relationships to disclose
Filippo Russo
No relevant relationships to disclose
Antonio Pinto
No relevant relationships to disclose